Appeals court reverses $1.2bn judgment against Gilead in BMS CAR-T caseGilead Sciences’ Kite Pharma has won a key victory on appeal in its long-running dispute with Bristol Myers Share XAppeals court reverses $1.2bn judgment against Gilead in BMS CAR-T casehttps://pharmaphorum.com/news/appeals-court-reverses-1-2bn-judgment-against-gilead-in-bms-car-t-case/
Alvotech files lawsuit challenging AbbVie’s Humira patent thicketBiosimilars firm Alvotech has filed a lawsuit that challenges AbbVie’s legal defences surrounding the inflammatory disease drug Humira Share XAlvotech files lawsuit challenging AbbVie’s Humira patent thickethttps://pharmaphorum.com/news/alvotech-files-lawsuit-challenging-abbvies-humira-patent-thicket/
Pfizer shares slump as support grows for COVID-19 vaccine patent waiverShares in COVID-19 vaccine manufacturers have taken a hit after the US signalled its support for waiving patents Share XPfizer shares slump as support grows for COVID-19 vaccine patent waiverhttps://pharmaphorum.com/news/pfizer-shares-slump-as-support-grows-for-covid-19-vaccine-patent-waiver/
Teva faces EU antitrust probe over MS drug CopaxoneThe European Commission has formally opened an antitrust investigation into Teva, which will assess whether the pharma company Share XTeva faces EU antitrust probe over MS drug Copaxonehttps://pharmaphorum.com/news/teva-faces-eu-antitrust-probe-over-ms-drug-copaxone/
AstraZeneca breathes sigh of relief as court blocks US Symbicort genericA US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing Share XAstraZeneca breathes sigh of relief as court blocks US Symbicort generichttps://pharmaphorum.com/news/astrazeneca-breathes-sigh-of-relief-as-court-blocks-us-symbicort-generic/
EU fines Teva and Cephalon €60.5m for ‘pay for delay’ schemeThe European Union has fined Teva and its neurology unit Cephalon €60.5 million for an elaborate “pay for Share XEU fines Teva and Cephalon €60.5m for ‘pay for delay’ schemehttps://pharmaphorum.com/news/eu-fines-teva-and-cephalon-e60-5m-for-pay-for-delay-scheme/
Amgen’s cancer biosimilars stay on US market as court battle with Roche endsAmgen has scored yet another home run in the US courts, this time seeing off a legal challenge Share XAmgen’s cancer biosimilars stay on US market as court battle with Roche endshttps://pharmaphorum.com/news/amgens-cancer-biosimilars-stay-on-us-market-as-court-battle-with-roche-ends/
Amgen wins latest round in legal tussle over Enbrel patentsAmgen’s reputation as a fearsome adversary in the courtroom remains intact after it won the latest round in Share XAmgen wins latest round in legal tussle over Enbrel patentshttps://pharmaphorum.com/news/amgen-wins-latest-round-in-legal-tussle-over-enbrel-patents/
AbbVie won’t enforce patents for COVID-19 drug candidate KaletraAbbVie has said it won’t defend patent rights to its HIV therapy Kaletra in the hope that it Share XAbbVie won’t enforce patents for COVID-19 drug candidate Kaletrahttps://pharmaphorum.com/news/abbvie-wont-enforce-patents-for-covid-19-drug-candidate-kaletra/
